Raymond James & Associates’s GenMark Diagnostics, Inc GNMK Stock Holding History

Raymond James & Associates’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,600	Closed	-$69K	–	3763
2019 Q2	$69K	Buy	+10,600	New	+$74.7K	﹤0.01%	3462
2019 Q1	–	Sell	-13,550	Closed	-$66K	–	3752
2018 Q4	$66K	Sell	13,550 -5,000	-27%	-$26K	﹤0.01%	3357
2018 Q3	$136K	Hold	18,550	–	–	﹤0.01%	3390
2018 Q2	$118K	Buy	18,550 +1,000	+6%	+$6.61K	﹤0.01%	3372
2018 Q1	$95K	Buy	17,550 +4,300	+32%	+$21.4K	﹤0.01%	3275
2017 Q4	$55K	Sell	13,250 -17,100	-56%	-$103K	﹤0.01%	3272
2017 Q3	$292K	Buy	30,350 +12,600	+71%	+$131K	﹤0.01%	2812
2017 Q2	$210K	Buy	+17,750	New	+$227K	﹤0.01%	2954

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's GNMK Position: Q3 2019 in Review

Raymond James & Associates sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2019, closing a stake of 10,600 shares — an estimated $69K sold.

Raymond James & Associates first reported a position in GNMK in Q2 2017 and held it in 8 quarters. The position peaked at $292K in Q3 2017. 110 funds tracked by Wall St. Rank hold GNMK as of Q3 2019.

Raymond James & Associates reported no remaining GenMark Diagnostics, Inc position as of Q3 2019 after selling out during the quarter.
Raymond James & Associates sold 10,600 GenMark Diagnostics, Inc shares in Q3 2019, an estimated $69K.
Raymond James & Associates first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 8 quarters.
Raymond James & Associates's GenMark Diagnostics, Inc position peaked at $292K in Q3 2017.
110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.